# reload+after+2024-01-21 12:45:59.877576
address1§11455 El Camino Real
address2§Suite 250
city§San Diego
state§CA
zip§92130
country§United States
phone§858 369 7100
website§https://www.meipharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
fullTimeEmployees§46
companyOfficers§[{'maxAge': 1, 'name': 'Mr. David M. Urso B.A., Esq., J.D.', 'age': 59, 'title': 'CEO, President & Director', 'yearBorn': 1964, 'fiscalYear': 2023, 'totalPay': 748458, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard G. Ghalie M.D., MBA', 'age': 65, 'title': 'Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2023, 'totalPay': 627759, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Justin J. File', 'age': 53, 'title': 'CFO & Corporate Secretary', 'yearBorn': 1970, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Yomara  Gomez-Naiden', 'title': 'Senior Vice President of Operations & Quality', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Nicole Chyoko Iida', 'title': 'Vice President of Legal Affairs', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne  Frese', 'title': 'Chief People Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert D. Mass', 'age': 69, 'title': 'Strategic Advisor', 'yearBorn': 1954, 'fiscalYear': 2023, 'totalPay': 201676, 'exercisedValue': 0, 'unexercisedValue': 384162}, {'maxAge': 1, 'name': 'Mr. David A. Walsey J.D., L.L.M.', 'title': 'Senior Vice President of Corporate Affairs', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
exDividendDate§1700092800
payoutRatio§0.0
beta§0.682
priceToSalesTrailing12Months§0.37366083
currency§USD
dateShortInterest§1702598400
forwardEps§-5.2
pegRatio§-15.2
exchange§NCM
quoteType§EQUITY
shortName§MEI Pharma, Inc.
longName§MEI Pharma, Inc.
firstTradeDateEpochUtc§1071757800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§75f4e209-abec-388e-adff-b91ac3ee4681
gmtOffSetMilliseconds§-18000000
targetHighPrice§42.0
targetLowPrice§8.0
targetMeanPrice§23.33
targetMedianPrice§20.0
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§9.599
grossMargins§1.1450701
ebitdaMargins§0.35241002
trailingPegRatio§None
